ArticleFrontiers in oncology2026
Case Report: S-100 negative primary esophageal malignant melanoma: surgical challenges and phenotypic evolution.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary malignant melanoma of the esophagus (PMME) is a rare malignancy associated with a dismal prognosis. Diagnosis typically relies on immunohistochemical markers such as HMB-45 and S-100. However, unlike its cutaneous counterpart, mucosal melanoma can present with an S-100 negative phenotype in a notable subset of cases, posing a significant diagnostic challenge. Furthermore, the optimal extent of lymphadenectomy (2-field vs. 3-field) remains controversial, particularly for elderly patients with limited physiological reserve. Case presentation: We report the case of a 64-year-old male presenting with progressive dysphagia. Endoscopy revealed a pigmented, polypoid mass in the middle esophagus. Due to severe abdominal adhesions from prior surgeries and the patient's advanced age, the surgical team adopted a "safety-first" strategy, performing an Ivor-Lewis esophagectomy with 2-field lymphadenectomy. Postoperative pathology confirmed PMME (pT1bN0M0). Immunohistochemistry revealed a rare phenotype: HMB-45 positive (+) but S-100 negative (-). Despite adjuvant maintenance therapy with Toripalimab (a PD-1 inhibitor), the patient developed a rapid cervical lymph node recurrence four months postoperatively. Notably, the recurrent tumor cells exhibited partial S-100 positivity, indicating phenotypic heterogeneity and antigenic drift. Conclusion: This case highlights the potential diagnostic pitfall of S-100 negativity in PMME and the phenomenon of phenotypic switching during metastasis. For elderly patients where 3-field lymphadenectomy is deemed too risky, the high potential for cervical skip metastasis necessitates rigorous postoperative surveillance. The rapid disease progression despite immunotherapy underscores the urgent need to explore more effective multimodal treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.